Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. [electronic resource]
Producer: 20081030Description: 1786-801 p. digitalISSN:- 1533-4406
- Adjuvants, Immunologic -- adverse effects
- Adolescent
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- adverse effects
- Autoimmune Diseases -- chemically induced
- Female
- Humans
- Infections -- chemically induced
- Interferon beta-1a
- Interferon-beta -- adverse effects
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Purpura, Thrombocytopenic -- chemically induced
- Thyroid Diseases -- chemically induced
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.